Sun appoints new CEO as net profit slumps on US woes
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has reported an 11% increase in net sales to Rs10.21 billion ($220 million) for the third quarter ended December 31st, 2009, driven by formulation sales in India. However, net profits fell by 17% to Rs3.39 billion, dented by a decline in the US business.